A genetic deletion of the serotonin transporter greatly enhances the reinforcing properties of MDMA in rats

Molecular Psychiatry

Volumn 19, Issue 5, 2014, Pages 534-535

  Oakly, A C ^a   Brox, B W ^a   Schenk, S ^a   Ellenbroek, B A ^a  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5,7 DIHYDROXYTRYPTAMINE; DOPAMINE; SEROTONIN; SEROTONIN TRANSPORTER; RNA BINDING PROTEIN; SEROTONIN RECEPTOR AFFECTING AGENT; SERT PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; CONTROLLED STUDY; DRUG ABUSE; DRUG SELF ADMINISTRATION; EXTRACELLULAR SPACE; GENE; GENE DELETION; LETTER; NERVE CELL; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; REDUCTION; REINFORCEMENT; REWARD; SEROTONIN RELEASE; SEROTONIN TRANSPORTER GENE; TISSUE LEVEL; ABUSE LIABILITY; ANIMAL BEHAVIOR; ANIMAL; DOSE RESPONSE; GENE INACTIVATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; PATHOPHYSIOLOGY; TRANSGENIC RAT;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE DELETION; GENE KNOCKOUT TECHNIQUES; KAPLAN-MEIER ESTIMATE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS, TRANSGENIC; REINFORCEMENT (PSYCHOLOGY); RNA-BINDING PROTEINS; SELF ADMINISTRATION; SEROTONIN AGENTS;

EID: 84899471816     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2013.75     Document Type: Letter

References (14)

1. Schenk S, Colussi-Mas J, Do J, Bird J. J Drug Alcohol Res 2012; 1: 1-6.
2. Han DD, Gu HH. BMC Pharmacol 2006; 6: 6.
3. Carroll ME, Lac ST, Asencio M, Kragh R. Pharmacol Biochem Behav 1990; 35: 237-244.
4. Baumann MH, Clark RD, Woolverton WL, Wee S, Blough BE, Rothman RB.J Pharmacol Exp Ther 2011; 337: 218-225.
5. Homberg JR, Olivier JDA, Smits BMG, Mul JD, Mudde J, Verheul M et al.Neuroscience 2007; 146: 1662-1676.
6. Leccese AP, Lyness WH. Brain Res 1984; 303: 153-162.
7. Pelloux Y, Dilleen R, Economidou D, Theobald D, Everitt BJ. Neuropsychopharmacology2012; 37: 2505-2514.
8. Bradbury S, Schenk S. Behav Pharmacol 2011; 22(Suppl A): e56.
9. Brennan KA, Carati C, Lea RA, Fitzmaurice PS, Schenk S. Behav Pharmacol 2009; 20:688-694.
10. Schenk S. Neurosci Biobehav Rev 2011; 35: 1203-1218.
11. Trigo JM, Renoir T, Lanfumey L, Hamon M, Lesch K-P, Robledo P et al. BiolPsychiatry 2007; 62: 669-679.
12. Easton N, Marsden CA. J Psychopharmacol 2006; 20: 194-210.
13. Martin-Santos R, Torrens M, Poudevida S, Langohr K, Cuyas E, Pacifici R et al.Addict Biol 2010; 15: 15-22.
14. Roiser JP, Rogers RD, Cook LJ, Sahakian BJ. Psychopharmacology 2006; 188: 213-227.